LOX expression and functional analysis in astrocytomas and impact of IDH1 mutation

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Da Silva, Roseli ^a   Uno, Miyuki ^a   Nagahashi Marie, Suely K ^a   Oba Shinjo, Sueli M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE 1; PROCOLLAGEN C PROTEINASE; PROTEIN LYSINE 6 OXIDASE; BMP1 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; OLR1 PROTEIN, HUMAN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1;

ADULT; ARTICLE; ASTROCYTOMA; BMP1 GENE; CANCER GRADING; CANCER PROGNOSIS; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HIF1A GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IDH1 GENE; IN VITRO STUDY; LOX GENE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; BIOSYNTHESIS; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ASTROCYTOMA; BONE MORPHOGENETIC PROTEIN 1; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOCITRATE DEHYDROGENASE; MUTATION; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; SCAVENGER RECEPTORS, CLASS E;

EID: 84925433508     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119781     Document Type: Article

References (65)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 2: 97-109. PMID: 17618441
2. Ohgaki H, Kleihues P. Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol. 2011; 28: 177-183. doi: 10.1007/s10014-011-0029-1 PMID: 21442241
3. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013; 19: 764-772. doi: 10.1158/1078-0432.CCR-12-3002 PMID: 23209033
4. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008; 116: 597-602. doi: 10.1007/s00401-008-0455-2 PMID: 18985363
5. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, et al. IDH1 mutations are present in the majority of common adult gliomas but are rare in primary glioblastomas. Neurol Oncol. 2009; 11: 341-347. doi: 10.1215/15228517-2009-025 PMID: 19435942
6. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009; 174: 1149-1153. doi: 10.2353/ajpath.2009.080958 PMID: 19246647
7. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765-773. doi: 10.1056/NEJMoa0808710 PMID: 19228619
8. Gravendeel LA, Kloosterhof NK, Bralten LB, Van Marion R, Dubbink HJ, Dinjens W, et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat. 2010; 1: E1186-E1199. doi: 10.1002/humu.21201 PMID: 20077503
9. Weller M, Wick W, von Deimling A. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Glia. 2011; 59: 1200-1204. doi: 10.1002/glia.21130 PMID: 21294161
10. Lai A, Kharbanda S, Pope WB. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011; 29: 4482-4490. doi: 10.1200/JCO.2010.33.8715 PMID: 22025148
11. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al. IDH1 mutations at residue p.R132 (IDH1(R132) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 2009; 1: 7-11.
12. Csiszar K. Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid Res Mol Biol. 2001; 70: 1-32. PMID: 11642359
13. Nishioka T, Eustace A, West C. Lysyl oxidase: from basic science to future cancer treatment. Cell Struct. Funct. 2012; 37: 75-80. PMID: 22453058
14. Smith-Mungo LI, Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol. 1998; 16: 387-398. PMID: 9524359
15. Erler JT, Bennewith KL, Nicolau M, Dornhöofer N, Kong C, Le QT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006; 440: 1222-1226. PMID: 16642001
16. Stewart GD, Gray K, Pennington CJ, Edwards DR, Riddick AC, Ross JA, et al. Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncol Rep. 2008; 20: 1561-1567. PMID: 19020742
17. Schietke R, Warnecke C, Wacker I, Schödel J, Mole DR, Campean V, et al. The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. J Biol Chem. 2010; 285: 6658-6669. doi: 10.1074/jbc.M109.042424 PMID: 20026874
18. Pez F, Dayan F, Durivault J, Kaniewski B, Aimond G, Le Provost GS, et al. The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res. 2011; 71: 1647-1657. doi: 10.1158/0008-5472.CAN-10-1516 PMID: 21239473
19. Laczko R, Szauter KM, Jansen MK, Hollosi P, Muranyi M, Molnar J, et al. Active lysyl oxidase (LOX) correlates with focal adhesion kinase (FAK)/paxillin activation and migration in invasive astrocytes. Neuropathol Appl Neurobiol. 2007; 33: 631-643. PMID: 17931358
20. Baker AM, Bird D, Welti JC, Gourlaouen M, Lang G, Reynolds AR et al. Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. Cancer Res. 2013; 73: 583-594. doi: 10.1158/0008-5472.CAN-12-2447 PMID: 23188504
21. Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA et al. Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol. 2013; 16: 686-695. doi: 10.1093/neuonc/not243 PMID: 24366912
22. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3: 1101-1108. PMID: 18546601
23. Uno M, Oba-Shinjo SM, Silva R, Miura F, Clara CA, Almeida JR, et al. IDH1 mutations in a Brazilian series of Glioblastoma. Clinics. 2011; 66: 163-165. PMID: 21437454
24. Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res. 2002; 62: 4478-4483. PMID: 12154058
25. Kagan HM, Trackman PC. Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol. 1991; 5: 206-210. PMID: 1680355
26. Cox TR, Erler J. Remodeling and homeostasis of the extracellular matrix: implications for fibroticdiseases and cancer. Dis Model Mech. 2011; 4: 165-178. doi: 10.1242/dmm.004077 PMID: 21324931
27. Erler JT, Weaver VM. Three-dimensional context regulation of metastasis. Clin Exp Metastasis. 2009; 26: 35-49. doi: 10.1007/s10585-008-9209-8 PMID: 18814043
28. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signalling. Cell. 2009; 139: 891-906. doi: 10.1016/j.cell.2009.10.027 PMID: 19931152
29. Ji F, Wang Y, Qiu L, Li S, Zhu J, Liang Z, et al. Hypoxia inducible factor 1α-mediated LOX expression correlates with migration and invasion in epithelial ovarian cancer. Int J Oncol. 2013; 42: 1578-1588. doi: 10.3892/ijo.2013.1878 PMID: 23545606
30. Maruhashi T, Kii I, Saito M, Kudo A. Interaction between periostin and BMP-1 promotes proteolytic activation of lysyl oxidase. J Biol Chem. 2010; 285: 13294-13303. doi: 10.1074/jbc.M109.088864 PMID: 20181949
31. Albinger-Hegyi A, Stoeckli SJ, Schmid S, Storz M, Iotzova G, Probst-Hensch NM, et al Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int J Cancer. 2010; 126: 2653-2662. doi: 10.1002/ijc.24948 PMID: 19816945
32. Baker AM, Cox TR, Bird D, Lang G, Murray GI, Sun XF et al. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer. J Natl Cancer Inst. 2011; 103: 407-424. doi: 10.1093/jnci/djq569 PMID: 21282564
33. Chen LC, Tu SH, Huang CS, Chen CS, Ho CT, Sun XF, et al. Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway. Breast Cancer Res Treat. 2012; 134: 989-1004. doi: 10.1007/s10549-012-1986-8 PMID: 22434522
34. Sakai M, Kato H, Sano A, Tanaka N, Inose R, Kimura H, et al. Expression of lysyl oxidase is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol. 2009; 16: 2494-2501. doi: 10.1245/s10434-009-0559-5 PMID: 19526206
35. Ping W, Jiang WY, Chen WS, Sun W, Fu XN. Expression and significance of hypoxia inducible factor-1α and lysyl oxidase in non-small cell lung cancer. Asian Pac J Cancer Prev. 2013; 14: 3613-3618. PMID: 23886154
36. Basuroy S, Dunagan M, Sheth P, Seth A, Rao RK. Hydrogen peroxide activates focal adhesion kinase and c-Src by a phosphatidylinositol 3 kinase-dependent mechanism and promotes cell migration in Caco-2 cell monolayers. Am J Physiol Gastrointest Liver Physiol. 2010; 299: G186-195. doi: 10.1152/ajpgi.00368.2009 PMID: 20378826
37. Sheridan PJ, Kozar LG, Benson SC. Increased lysyl oxidase activity in aortas of hypertensive rats and effect of betaaminopropionitrile. Exp Mol Pathol. 1979; 30: 315-324. PMID: 33826
38. Arem AJ, Madden JW, Chvapil M, Tillema L. Effect of lysyl oxidase inhibition of healing wounds. Surg Forum. 1975; 26: 67-69. PMID: 2992
39. Lazarus HM, Cruikshank WW, Narasimhan N, Kagan HM. Center DM. Induction of human monocyte motility by lysyl oxidase. Matrix Biol. 1995; 14: 727-731. PMID: 8785587
40. Abourbih DA, Di Cesare S, Orellana ME, Antecka E, Martins C, Petruccelli LA, et al. Lysyl oxidase expression and inhibition in uveal melanoma. Melanoma Res. 2010; 20: 97-106. doi: 10.1097/CMR.0b013e328336edfe PMID: 20179655
41. Osawa T, Ohga N, Akiyama K, Hida Y, Kitayama K, Kawamoto T, et al. Lysyl oxidase secreted by tumour endothelial cells promotes angiogenesis and metastasis. Br J Cancer. 2013; 109: 2237-2247. doi: 10.1038/bjc.2013.535 PMID: 24045659
42. Shih YH, Chang KW, Chen MY, Yu CC, Lin DJ, Hsia SM, et al. Lysyl oxidase and enhancement of cell proliferation and angiogenesis in oral squamous cell carcinoma. Head Neck. 2013; 35:250-256. doi: 10.1002/hed.22959 PMID: 22367676
43. Yang X, Li S, Li W, Chen J, Xiao X, Wang Y et al. Inactivation of lysyl oxidase by β-aminopropionitrile inhibits hypoxia-induced invasion and migration of cervical cancer cells. Oncol Rep. 2013; 29: 541-548 doi: 10.3892/or.2012.2146 PMID: 23165370
44. Bondareva A, Downey CM, Ayres F, Liu W, Boyd SK, Hallgrimsson B, et al. The lysyl oxidase inhibitor, beta aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells. PLoS ONE. 2009; 4: e5620. doi: 10.1371/journal.pone.0005620 PMID: 19440335
45. Wiel C, Augert A, Vincent DF, Gitenay D, Vindrieux D, Le Calvé B, et al. Lysyl oxidase activity regulates oncogenic stress response and tumorigenesis. Cell Death Dis. 2013; 4: e855. doi: 10.1038/cddis.2013.382 PMID: 24113189
46. Mammoto T, Jiang A, Jiang E, Panigrahy D, Kieran MW, Mammoto A. Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression. Am J Pathol. 2013; 183: 1293-1305. doi: 10.1016/j.ajpath.2013.06.026 PMID: 23928381
47. Dong Y, Xie X, Wang Z, Hu C, Zheng Q, Wang Y, et al. Increasing matrix stiffness upregulates vascular endothelial growth factor expression in hepatocellular carcinoma cells mediated by integrin β1. Biochem Biophys Res Commun. 2014; 444: 427-432. doi: 10.1016/j.bbrc.2014.01.079 PMID: 24472554
48. Lee K A, Burgoon LD, Lamb L, Dere E, Zacharewski TR, Hogenesch JB, et al. Identification and characterization of genes susceptible to transcriptional cross-talk between the hypoxia and dioxin signaling cascades. Chem Res Toxicol. 2006; 19: 1284-1293. PMID: 17040097
49. Mustafa D, Swagemakers S, French P, Luider TM, van der Spek P, Kremer A, et al. Structural and expression differences between the vasculature of pilocytic astrocytomas and glioblastomas. J Neuropathol Exp Neurol. 2013; 7: 1171-1181.
50. Bond JS, Beynon RJ. The astacin family of metalloendopeptidases. Protein Sci. 1995 4: 1247-1261. PMID: 7670368
51. Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS. Bone morphogenetic protein-1: The type I procollagen C-proteinase. Science. 1996; 271: 360-362. PMID: 8553073
52. Sterchi EE, Stöcker W, Bond JS. Meprins, membrane-bound and secreted astacin metalloproteinases. Mol Aspects Mol. 2008; 29: 309-328. doi: 10.1016/j.mam.2008.08.002 PMID: 18783725
53. Ge G, Greenspan DS. Developmental roles of the BMP1/TLD metalloproteinases. Birth Defects Res C Embryo Today. 2006; 78: 47-68. PMID: 16622848
54. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-1812. doi: 10.1126/science.1164382 PMID: 18772396
55. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer. 2009; 15: 6002-6007. doi: 10.1158/1078-0432.CCR-09-0715 PMID: 19755387
56. Uno M, Oba-Shinjo SM, de Aguiar PH, Leite CC, Rosemberg S, Miura FK, et al. Detection of somatic TP53 splice site mutations in diffuse astrocytomas. Cancer Lett. 2005; 224: 321-327. PMID: 15914282
57. Carvalho PO, Uno M, Oba-Shinjo SM, Rosemberg S, Wakamatsu A, da Silva CC, et al. Activation of EGFR signaling from pilocytic astrocytomas to glioblastomas. Int J Biol Markers. 2014; 29: e120-8. doi: 10.5301/JBM.5000045 PMID: 24170555
58. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17: 510-522. doi: 10.1016/j.ccr.2010.03.017 PMID: 20399149
59. Kaneda A, Wakazono K, Tsukamoto T, Watanabe N, Yagi Y. Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res. 2004; 64: 6410-6415. PMID: 15374948
60. Li PA, He Q, Cao T, Yong G, Szauter KM, Fong KS, et al. Up-regulation and altered distribution of lysyl oxidase in the central nervous system of mutant SOD1 transgenic mouse model of amyotrophic lateral sclerosis. Brain Res Mol Brain Res. 2004; 120: 115-122. PMID: 14741400
61. Li W, Nellaiappan K, Strassmaier T, Graham L, Thomas KM, Kagan HM. Localization and activity of lysyl oxidase within nuclei of fibrogenic cells. Proc Natl Acad Sci USA. 1997; 94: 12817-12822. PMID: 9371758
62. Nellaiappan K, Risitano A, Liu G, Nicklas G, Kagan HM. Fully processed lysyl oxidase catalyst translocates from the extracellular space into nuclei of aortic smooth-muscle cells. J Cell Biochem. 2000; 79: 576-582. PMID: 10996848
63. Saad FA, Torres M, Wang H, Graham L. Intracellular lysyl oxidase: effect of a specific inhibitor on nuclear mass in proliferating cells. Biochem Biophys Res Commun. 2010; 39: 944-949.
64. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J. Cell Biochem. 2003; 88: 660-672. PMID: 12577300
65. El-Osta A, Wolffe AP. DNA methylation and histone deacetylation in the control of gene expression: basic biochemistry to human development and disease. Gene Expr. 2000; 9: 63-75. PMID: 11097425